RNAZ vs SRE · $5.1M cap vs P/E 31, rev $13.70B
Transcode Therapeutics Inc (RNAZ) versus Sempra Energy (SRE) — a side-by-side from cached financials, not a winner call.
Transcode Therapeutics Inc (RNAZ) is a biotechnology company listed on NASDAQ.
Sempra Energy (SRE) is a utilities - diversified company listed on US.
RNAZ does not have a complete income-statement cache yet.
Latest reported SRE revenue for 2025-12-31 was $13.70B. Net income was $1.84B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. SRE currently screens at market cap $59.76B and trailing P/E 31.1.
RNAZ currently screens at market cap $5.1M. SRE currently screens at market cap $59.76B and trailing P/E 31.1.
Not investment advice. Open the RNAZ and SRE stock pages for the full models.
Not investment advice.